

[Adalimumab](#)

Statut de médicament essentiel

Section:

[29. Medicines for diseases of joints](#) [29.3. Medicines for juvenile joint diseases](#)

Codes ATC: [L04AB04](#)

EMLc

Indication

Juvenile idiopathic arthritis Code ICD11: [FA24.Z](#)

INN

Adalimumab

Type de médicament

Biological agent

Type de liste

Liste complémentaire

Additional notes

EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars.

EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.

Formulations

Parenteral > General injections > SC: 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)

Historique des statuts LME

Ajouté pour la première fois en 2019 ([TRS 1021](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

[certolizumab pegol](#) (Codes ATC: [L04AB05](#))

[etanercept](#) (Codes ATC: [L04AB01](#))

[golimumab](#) (Codes ATC: [L04AB06](#))

[infliximab](#) (Codes ATC: [L04AB02](#))

Renseignements sur le brevet

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Lire la suite [sur les brevets](#).

Balises

Biological

Wikipédia

[Adalimumab](#)

DrugBank

[Adalimumab](#)

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc. Listing of adalimumab for the indication of juvenile idiopathic arthritis was transferred from Section 8.1 (Immunomodulators for non-malignant disease) to Section 29.3 (Juvenile joint diseases).